Leerink Partners analyst Jason Gerberry bumped his price target on Outperform-rated Momenta Pharmaceuticals (NASDAQ: MNTA) to $26.00 (from $25.00) following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE